MedTech Industry Pulse: February 2026
Avania’s monthly briefing on the trends shaping MedTech regulatory strategy, funding, and market access, part of our MedTech insights and resources library. Here’s what mattered in February 2026.
Prefer a PDF to save or share internally? Download the full February 2026 report (PDF)
February 2026 at a glance
- MedTech clinical trial starts reached 111 in February, a 30.6 percent increase over February 2025 but an 11.2 percent drop from January 2026. Cardiovascular, neurology, ophthalmology, and oncology together account for 48 percent of all study starts year to date.
- More than $200M was raised in January 2026 combined between Neurent Medical, Chamber, Temple, and Polares Medical, with AI-enabled technologies gaining momentum among VC investors.
- FDA granted five PMA approvals, to Synergy Spine Solutions, Allurion Technologies, Empirical Spine, Novocure, and Contamac, plus two De Novo approvals, to Ultrasound AI and Amferia AB.
- 219 510(k)s were filed in February, down 8.7 percent from January 2026.
MedTech Companies With Funding Reported in February 2026
AI-enabled companies were a notable theme this month, including Chamber, Omniscient Neurotechnology, Brainomix, AI-Stroke, Hemi Health, JuneBrain, VoiceMed, and Neuropacs.
| Company | Country | Stage | Focus | Amount |
|---|---|---|---|---|
| Neurent Medical | Ireland | Series C | Minimally invasive ENT device for chronic rhinitis treatment | €62.5M |
| Chamber | USA | Series A | Data and AI-enabled cardiology care platform to manage heart disease | $60M |
| Temple | US / India | Seed | Brain monitoring wearable | $54M |
| Polares Medical | Switzerland / USA | Series C | Posterior leaflet replacement system for mitral regurgitation | $50M |
| ShanX Medtech | Netherlands | Seed round | Rapid diagnostic system identifying the most effective antibiotic in about one hour | ≈€24M |
| Omniscient Neurotechnology | Australia | Series D | AI-enabled connectomics tools for brain mapping, neurosurgery, stroke, TBI | $20M |
| Lifeaz | France | Equity funding / expansion | Connected defibrillator developer | €13M |
| Avisi Technologies | USA | Series A | Glaucoma surgical implant | $10.7M |
| Enspire DBS Therapy | USA | Series B1 | Deep brain stimulation therapy for post-stroke recovery | $10.3M |
| Synchrony Medical | USA | Venture / Investor Funding | At-home respiratory care and airway clearance system | $5.0M |
| Brainomix | UK/EU/USA | Series C extension | AI-powered radiology imaging platforms for stroke and lung fibrosis | £4.8M |
| AI-Stroke | USA | Seed round | AI platform for pre-CT stroke triage | $4.6M |
| Hemi Health | Denmark | Seed round | Sensor-integrated platform for migraine and concussion care | ≈€4M |
| JuneBrain | USA | Private funding + ETC | Wearable AI retinal imaging platform for neurological disease diagnosis | ≈$3.4M |
| ATRO Medical | Netherlands | Equity financing | Artificial meniscus implants | €3M |
| Neupulse | UK | Equity funding / expansion | Wearable neuromodulation device for Tourette’s | £3.0M |
| Orthofuse | UK | Seed funding | 3D-printed orthopedic implant systems | €2.2M |
| VoiceMed | Italy | First funding round | AI/voice biomarker based remote respiratory monitoring and screening | €1M |
| Entirety Biomedical | USA | Seed financing | Bioabsorbable orthopedic fixation implants | $1.2M |
| Neuropacs | USA | Early Stage | AI-driven neurological diagnostics for parkinsonian disorders | ≈$1M |
Year-to-Date MedTech Planned and Completed M&A
| Buyer | Target | Approx. Value / Focus |
|---|---|---|
| Smith & Nephew | Integrity Orthopaedics | ≈$450M, rotator cuff repair devices |
| Boston Scientific | Valencia Technologies | Neuromodulation tech |
| BioStem Technologies | BioTissue Surgical & Wound Care | ≈$15M plus milestones, surgical and wound care products |
| W. L. Gore & Associates | Conformal Medical | Structural heart implants |
| Haemonetics | Vivasure Medical | ≈€185M, vascular closure devices |
| Resonetics | Resolution Medical | Expands structural heart and neuromodulation design and manufacturing |
| Boston Scientific | Penumbra | ≈$14.5B, vascular and neuro devices |
| BD & Waters | n/a (combination) | Diagnostics and biosciences |
| Medtronic | CathWorks | ≈$585M, cardiac devices |
| Precision IO Group / Quantum Surgical | NeuWave Medical | Robotics plus tumor ablation tech |
| Zavation | ChoiceSpine | Spine devices |
| GCM | Kettmann Machining | Precision MedTech manufacturing |
| Maxx Orthopedics | TracPatch | Remote orthopedic monitoring |
| Danaher | Masimo | $9.9B, patient monitoring |
| Guardant Health | MetaSight | $59M, diagnostics |
| Tactile Medical | LymphaTech | $6.8M plus milestones, lymphedema digital and device |
Regulatory and Market Access Trends
February brought the biggest US quality system overhaul in 30 years, the first generative AI chatbot to earn FDA Breakthrough Designation, and hard EUDAMED deadlines for Europe. Regulators across major markets are converging on AI governance and mutual recognition.
QMSR fully replaced QSR as of February 2, with ISO 13485:2016 now governing US device quality systems; QSIT is withdrawn in favor of a new inspection program, CP 7382.850. FDA and CMS also activated a TEMPO pilot March 2, sending follow-ups to up to 10 digital health device manufacturers per clinical area. Separately, RecovryAI’s LLM-powered post-surgical virtual care assistant earned FDA Breakthrough Device Designation March 3, described as the first generative AI chatbot to do so and a potential game changer for the Class II SaMD pathway. Given the pace of change here, this is a good moment to revisit regulatory strategy and submissions planning against the new QMSR audit expectations.
EUDAMED becomes mandatory May 28, 2026, with four modules, Actor Registration, UDI/Device, NB/Certificates, and Market Surveillance, going live and no further voluntary use permitted. The European Commission is expected to propose targeted MDR/IVDR simplification, though legacy device transitions remain a compliance flashpoint. Notified Body capacity is expanding, with 51 Notified Bodies now designated under MDR per NANDO, and harmonization plans for timelines, pricing, and recertification are underway.
Mandatory hospital adverse event reporting took effect March 21, requiring all public, private, and day hospitals to report device-related injuries to the TGA, with integration into accreditation standards planned by 2030. Implant UDI requirements arrive in July 2026, making barcodes mandatory on all implantable device packaging and in a public database, a shift worth factoring into market access and reimbursement strategy planning for the Australian market. The TGA also released new AI/SaMD guidance in February clarifying when AI software qualifies as a medical device, with SaMD listed as a focus area for 2026 to 2027.
Revised GMP requirements take effect November 1, 2026, aligning with ISO 13485, EU MDR, and FDA QMSR and introducing full lifecycle governance covering outsourced R&D and CMOs. NMPA’s 2026 Standards Revision Plan, released January 28, updates 80 device standards, one mandatory and 79 recommended, for international alignment.
FDA was recognized as an equivalent authority effective May 1, letting US-cleared devices with Japanese predicates earn PMDA priority review in what is described as the largest US-Japan regulatory alignment in a decade. Japan’s IDATEN framework continues expanding toward adaptive, continuous-learning AI post-market modification, with roughly 100 AI-enabled SaMDs now approved.
Navigating Global Disruptions: Operational Impact on MedTech Trials
The source material frames concurrent global disruption as compounding risk for MedTech clinical trials and device supply chains worldwide, with clinical trial site-level risk assessment, supply chain rerouting, and data continuity planning becoming a priority in affected regions.
Medical devices are not exempt from US tariffs, which the source material puts at 10 to 50 percent depending on country of origin. A Section 232 investigation expected in spring 2026 is described as affecting 62 percent of imported US medical devices. Clinical trial sponsors are advised to reassess the landed cost impact on study budgets and customs timing for investigational product.
- Shipment and flight delays: the source material describes regional trials as potentially affected by airspace closures in Iran, the UAE, Qatar, Kuwait, Bahrain, Iraq, and Lebanon starting February 28, with sponsors running active trial sites in the Gulf, Israel, and Lebanon facing shipment delays and site disruption.
- Healthcare IT outages: the source material describes cloud data center damage (AWS) in the UAE and Bahrain on March 2 as the first major cloud outage affecting public health attributed to military action. Sponsors with electronic systems at Middle East trial sites, including EDC, eCOA, or safety databases, are advised to verify data integrity, confirm backup and archival to unaffected regions, and ensure access to offline or paper systems where needed.
Clinical Trial Starts by Therapeutic Area
Interventional, industry-funded device trial starts reached 111 in February 2026, up 30.6 percent year over year but down 11.2 percent from January’s 125. By therapeutic area, cardiology and vascular led with 37 study starts, followed by neurology and neuroscience at 30, ophthalmology at 23, and oncology at 21; together, cardiovascular, neurology, ophthalmology, and oncology represent 48 percent of all study starts year to date. See Avania’s cardiovascular clinical trials experience for more on how this therapeutic area is trending.
FDA PMA Approvals, February 2026
- Synergy Disk (Synergy Spine Solutions): described as the first and only artificial cervical disc designed to improve alignment and provide intentional motion preservation.
- Allurion Gastric Balloon System (Allurion Technologies): described as the only FDA-approved Smart Capsule that transforms into a gastric balloon, combined with nutrition support and digital tools.
- LimiFlex Dynamic Sagittal Tether (Empirical Spine): a potential alternative to spinal fusion for patients receiving surgical decompression for grade 1 lumbar degenerative spondylolisthesis with spinal stenosis.
- Optune Pax (Novocure): intended for treatment of adult patients with locally advanced pancreatic cancer, used concomitantly with gemcitabine and nab-paclitaxel.
- Optimum Infinite (tisilfocon A) Orthokeratology Lenses II (Contamac): overnight-wear lenses indicated for the reduction of refractive error in non-diseased eyes.
FDA De Novo Approvals, February 2026
- Delivery Date AI (Ultrasound AI): a cloud-based software that predicts a baby’s due date using second- and third-trimester ultrasound images, using deep learning to analyze fetal development as an alternative to traditional calendar-based dating methods. Review advisory committee: Radiology.
- Amferia Wound Dressing (Amferia AB): a solid wound dressing pad that the source material describes as able to “bind and kill 99.99% of bacteria, providing an effective, clean environment for wound recovery.” Review advisory committee: General and Plastic Surgery.
510(k) Filing Trend
219 510(k)s were filed in February 2026, down 8.7 percent from January’s 239.
Frequently Asked Questions
It’s Avania’s monthly briefing on MedTech regulatory changes, funding trends, clinical trial activity, and M&A, built for device, diagnostic, and digital health companies tracking the global landscape.
QMSR fully replaced QSR as of February 2, 2026, aligning US device quality systems with ISO 13485:2016 and introducing a new FDA inspection program in place of QSIT.
US tariff policy and Middle East airspace and infrastructure disruptions are prompting clinical trial sponsors to reassess study budgets, customs timing, and data continuity plans for affected trial sites.
Catch up on the March 2026 MedTech Industry Pulse for the latest on Q1 2026 funding trends and MedTech cybersecurity.
Get Your Copy Now
Ready to Advance
Your MedTech?
Let's Accelerate Your Journey.